Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease

FASEB Journal

Volumn 28, Issue 5, 2014, Pages 2171-2176

  Koeberl, Dwight D ^a   Austin, Stephanie ^a   Case, Laura E ^b   Smith, Edward C ^c   Buckley, Anne F ^a   Young, Sarah P ^a   Bali, Deeksha ^a   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Division of Doctor of Physical Therapy   (United States)

^c Division of Medical Genetics   (United States)

Author keywords

Acid maltase; Acid glucosidase; Glycogen storage disease type II; Mannose 6 phosphate receptor

Indexed keywords

CATION INDEPENDENT MANNOSE 6 PHOSPHATE RECEPTOR; CREATINE KINASE; EOSIN; GLUCAN 1,4 ALPHA GLUCOSIDASE; HEMATOXYLIN; SALBUTAMOL; SOMATOMEDIN B RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENZYME REPLACEMENT; EVENING DOSAGE; FEMALE; FORCED VITAL CAPACITY; GLYCOGEN STORAGE DISEASE TYPE 2; GRIP STRENGTH; HAND GRIP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MORNING DOSAGE; MUSCLE BIOPSY; MUSCLE HYPERTROPHY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; URINE RETENTION; WESTERN BLOTTING;

ACID MALTASE; ACID Α-GLUCOSIDASE; GLYCOGEN STORAGE DISEASE TYPE II; MANNOSE-6-PHOSPHATE RECEPTOR;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; BIOPSY; ELECTROCARDIOGRAPHY; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HAND STRENGTH; HUMANS; MALE; MUSCLE, SKELETAL; PILOT PROJECTS; QUADRICEPS MUSCLE; RECEPTOR, IGF TYPE 2; TIME FACTORS; TREATMENT OUTCOME; WALKING;

EID: 84900993196     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-241893     Document Type: Article

References (20)

1. Raben, N., Danon, M., Gilbert, A. L., Dwivedi, S., Collins, B., Thurberg, B. L., Mattaliano, R. J., Nagaraju, K., and Plotz, P. H. (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 80, 159-169
2. Raben, N., Fukuda, T., Gilbert, A. L., de Jong, D., Thurberg, B. L., Mattaliano, R. J., Meikle, P., Hopwood, J. J., Nagashima, K., Nagaraju, K., and Plotz, P. H. (2005) Replacing acid alphaglucosidase in Pompe disease: Recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol. Ther. 11, 48-56
3. Koeberl, D. D., Luo, X., Sun, B., McVie-Wylie, A., Dai, J., Li, S., Banugaria, S. G., Chen, Y. T., and Bali, D. S. (2011) Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol. Genet. Metab. 103, 107-112
4. Koeberl, D. D., Li, S., Dai, J., Thurberg, B. L., Bali, D., and Kishnani, P. S. (2012) Beta2 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol. Genet. Metab. 105, 221-227
5. Caruso, J. F., Signorile, J. F., Perry, A. C., Leblanc, B., Williams, R., Clark, M., and Bamman, M. M. (1995) The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med. Sci. Sports Exerc. 27, 1471-1476
6. Kissel, J. T., McDermott, M. P., Mendell, J. R., King, W. M., Pandya, S., Griggs, R. C., and Tawil, R. (2001) Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57, 1434-1440
7. Angelini, C., Marsala, S. Z., L. Vergani, Nascimbeni, A. C., Fulizio, L., and Fanin, M. (2004) Adult acid maltase deficiency: an open trial with albuterol and branched-chain aminoacids. Basic Appl. Myol. 14, 71-78
8. Amalfitano, A., McVie-Wylie, A. J., Hu, H., Dawson, T. L., Raben, N., Plotz, P., and Chen, Y. T. (1999) Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc. Natl. Acad. Sci. U. S. A. 96, 8861-8866
9. Sun, B., Zhang, H., Franco, L. M., Young, S. P., Schneider, A., Bird, A., Amalfitano, A., Chen, Y. T., and Koeberl, D. D. (2005) Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 11, 57-65
10. Young, S. P., Stevens, R. D., An, Y., Chen, Y. T., and Millington, D. S. (2003) Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-eletrospray inonization tandem mass spectrometry. Anal. Biochem. 316, 175-180
11. Young, S. P., Zhang, H., Corzo, D., Thurberg, B. L., Bali, D., Kishnani, P. S., and Millington, D. S. (2009) Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet. Med. 11, 536-541
12. Matsumoto, T., Akutsu, S., Wakana, N., Morito, M., Shimada, A., and Yamane, A. (2006) The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat. Arch. Oral Biol. 51, 603-611
13. Van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., Lange, D. J., Leshner, R. T., Mayhew, J. E., Morgan, C., Nozaki, K., Park, D. J., Pestronk, A., Rosenbloom, B., Skrinar, A., van Capelle, C. I., van der Beek, N. A., Wasserstein, M., and Zivkovic, S. A. (2010) A randomized study of alglucosidase alfa in late-onset Pompe's disease. N. Engl. J. Med. 362, 1396-1406
14. Li, S., Sun, B., Nilsson, M. I., Bird, A., Tarnopolsky, M. A., Thurberg, B. L., Bali, D., and Koeberl, D. D. (2013) Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB J. 27, 34-44
15. McVie-Wylie, A. J., Lee, K. L., Qiu, H., Jin, X., Do, H., Gotschall, R., Thurberg, B. L., Rogers, C., Raben, N., O'Callaghan, M., Canfield, W., Andrews, L., McPherson, J. M., and Mattaliano, R. J. (2008) Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol. Genet. Metab. 94, 448-455
16. Zhu, Y., Jiang, J. L., Gumlaw, N. K., Zhang, J., Bercury, S. D., Ziegler, R. J., Lee, K., Kudo, M., Canfield, W. M., Edmunds, T., Jiang, C., Mattaliano, R. J., and Cheng, S. H. (2009) Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17, 954-963
17. Cardone, M., Porto, C., Tarallo, A., Vicinanza, M., Rossi, B., Polishchuk, E., Donaudy, F., Andria, G., De Matteis, M. A., and Parenti, G. (2008) Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 1, 6
18. Reagan-Shaw, S., Nihal, M., and Ahmad, N. (2008) Dose translation from animal to human studies revisited. FASEB J. 22, 659-661
19. Fowler, E. G., Graves, M. C., Wetzel, G. T., and Spencer, M. J. (2004) Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology 62, 1006-1008
20. Skura, C. L., Fowler, E. G., Wetzel, G. T., Graves, M., and Spencer, M. J. (2008) Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 70, 137-143